On April 1st, 2026, the FDA approved Foundayo™ (orforglipron), a once‑daily oral GLP‑1 receptor agonist for adults with obesity or overweight with weight‑related medical conditions. Foundayo is the first GLP‑1 pill for weight loss that can be taken at any time of day without food or water restrictions, offering a more flexible option compared to injectable GLP‑1 medications.
What Foundayo Is Approved For
Foundayo is approved for adults who:
- Have obesity, or
- Are overweight with weight‑related medical problems,
and are using the medication alongside a reduced‑calorie diet and increased physical activity.
It should not be used with other GLP‑1 receptor agonists.
How Well It Works: Key Clinical Trial Results
Foundayo was evaluated in the ATTAIN Phase 3 clinical trial program, which enrolled more than 4,500 adults.
ATTAIN‑1 (Adults without diabetes)
At the highest dose:
- Average weight loss: 27.3 lbs (12.4%) among participants who completed treatment
- Placebo comparison: 2.2 lbs (0.9%)
Across all participants (including those who discontinued early):
- Average weight loss: 25 lbs (11.1%)
- Placebo: 5.3 lbs (2.1%)
Cardiometabolic improvements
Participants also saw reductions in:
- Waist circumference
- Non‑HDL cholesterol
- Triglycerides
- Systolic blood pressure
Why This Approval Matters
Fewer than 1 in 10 eligible adults currently use GLP‑1 medications, often due to access barriers, stigma, or the complexity of injectable treatments. Foundayo’s oral, once‑daily format may expand access for people who prefer a pill over injections.
How to Take It
- One tablet daily, with or without food
- Tablets must be swallowed whole
- If a dose is missed, take it as soon as possible — but never take two doses in one day
Safety Information
Foundayo carries a boxed warning for potential thyroid tumors, including medullary thyroid carcinoma (MTC). It should not be used by individuals with:
- Personal or family history of MTC
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Serious risks include:
- Pancreatitis
- Severe gastrointestinal issues
- Dehydration leading to kidney problems
- Hypoglycemia (when used with insulin or sulfonylureas)
- Gallbladder problems
- Serious allergic reactions
Common side effects:
- Nausea
- Constipation or diarrhea
- Vomiting
- Indigestion
- Abdominal pain
- Headache
- Fatigue
- Hair loss
Availability and Cost
Foundayo will be available through LillyDirect® with:
- $25/month for eligible commercially insured patients
- $149/month for self‑pay
- $50/month for eligible Medicare Part D patients starting July 2026
Retail pharmacy and telehealth availability will follow shortly after LillyDirect fulfillment begins.
The Bottom Line
Foundayo is the first flexible, once‑daily oral GLP‑1 pill for weight loss, offering meaningful weight reduction and cardiometabolic benefits in clinical trials. Its approval expands treatment options for adults seeking non‑injectable obesity therapies.
Source: Read the official Lilly press release here.
Disclaimer: Health Evidence Digest provides general information about health research. Content is for informational purposes only and is not a substitute for professional medical advice.
Leave a Reply